Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00304850
Other study ID # 9258-03
Secondary ID 2002-004
Status Completed
Phase Phase 2
First received March 17, 2006
Last updated December 24, 2009
Start date March 2006
Est. completion date May 2009

Study information

Verified date December 2009
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

After surgery, sensitization and hyperexcitability of central nervous system result in acute and long lasting postoperative pain. It has been shown that N-methyl-D-aspartate (NMDA) receptors antagonist (such as ketamine) prevent this adverse neuroplasticity and potentiate analgesic drugs efficacy. Polyamines (putrescine, spermidine, spermine) are essential components of cells functioning and are also known as allosteric modulators of NMDA receptors. In animal studies, polyamine-free diet has confirmed these antinociceptive properties. This research aims at evaluating anti hyperalgesic properties of polyamine-free diet in women operated on breast cancer versus kétamine


Description:

This multicentric, single blind study will enrol 160 women (18-75 years old) operated on tumorectomy and adenectomy (T1, T2, T3, N0, N1, M0) for breast cancer. Patients will be randomly assigned in a 2x2 factorial plan : Group 1 = control (n = 40) ; group 2 = ketamine group administered during and 48 hours after a standardized anesthesia (n = 40) ; group 3 = polyamine-free diet, 1 week and 72 hours after surgery (n = 40) ; group 4 : ketamine + polyamine-free diet (n = 40).

The amount of morphine for the 24 first postoperative hours will be compared between each group as well as pain score, allodynia (Von Frey filaments) and hyperalgesia (algometer). Chronic pain occurrence (post-mastectomy pain syndrome) will be evaluated at 3 and 6 months using adequate questionnaire ( analgesic scale). Diet observance will be controlled preoperatively by a dosage of polyamines in circulating red cells blood.

Polyamines deprivation and ketamine ability to reduce postoperative pain will be compared (isobolographic method). Anti-hyperalgesic properties of ketamine have already been demonstrated in urologic, orthopaedic and abdominal surgery. In case of additive or synergistic effect of a polyamine deprivation such a strategic could be helpful to achieve better postoperative rehabilitation in reducing chronic pain after surgery.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date May 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Breast cancer (T1, T2, T3, N0, N1, M0)

- Age : 18 - 75

- Asa 1-3

- left or right tumorectomy with complete lymphadenectomy

- left or right complete mastectomy with complete lymphadenectomy

- complete lymphadenectomy within one week following simple tumorectomy

- informed consent signed

Exclusion Criteria:

- inflammatory tumor requiring pre-operative radiotherapy

- previous history of total mastectomy or partial contralateral mastectomy

- chronic inflammatory disease treated by corticoids or NSAI

- chronic analgesic treatment

- anti-arrhythmic or anti-epileptic treatments

- morphinic treatment during the 7 days before surgery

- excessive alcohol consumption or addiction

- ketamine or neomycin contra-indication

- severe cardiovascular disease

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
polyamine-free diet
Polyamine-free diet in the 7 days befor surgery
Drug:
Ketamine or placebo
Peroperative and post operative (48h) ketamine injection

Locations

Country Name City State
France CLCC-Institut Bergonie, service d'anesthésie réanimation, 229 cours de l'Argonne Bordeaux
France département d'anesthésie-réanimation 3, hôpital Pellegrin Bordeaux
France CLCC Alexis Vautrin Nancy
France APHParis Hôpital Pitié Salpétrière - Dépt. d'anesthésie réanimation Paris
France CLCC Réné Huguenin de Saint Cloud Saint Cloud

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Bordeaux Insurance CNP foundation, Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Morphine requirement for the 24 postoperative hours No
Secondary Pain intensity for the 4 days (and possibly at 7th day if the patient is still hospitalized) after surgery 4 days No
Secondary Allodynia measurements inclusion, 1, 2, 4 and 7 ddays after surgery No
Secondary Hyperesthesia measurements inclusion, 1, 2, 4 and 7 ddays after surgery No
Secondary Chronic pain incidence 3 and 6 months No
Secondary Late allodynia and/or hyperesthesia 6 months No
Secondary safety of treatment Along each patient folow-up Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2